Lipoprotein(a) and Cardiovascular Diseases　- Revisited

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Elevated lipoprotein(a) (Lp(a)) concentrations are linked to cardiovascular disease (CVD).
• Previous lack of Lp(a)-lowering therapies and evidence hindered establishing its importance.
• Recent genetic and clinical research highlights Lp(a)'s causal role in CVD pathogenesis.

Purpose of the Study:

• To review the established role of Lp(a) in cardiovascular disease.
• To discuss emerging therapeutic strategies for lowering Lp(a) levels.
• To address residual cardiovascular risk in the era of statin therapy.

Main Methods:

• Review of recent clinical and genetic research on Lp(a).
• Analysis of Mendelian randomization studies demonstrating Lp(a)'s causal role in CVD.
• Evaluation of novel therapeutic strategies for Lp(a) reduction.

Main Results:

• Lp(a) is causally linked to coronary artery disease, calcified aortic valve disease, stroke, and heart failure, independent of LDL-C.
• Conventional therapies have not effectively reduced Lp(a) levels.
• Emerging therapies, including PCSK9 inhibitors and antisense oligonucleotides, show significant Lp(a)-lowering potential.

Conclusions:

• Lipoprotein(a) is a critical, independent risk factor for cardiovascular disease.
• Novel therapeutic approaches offer effective strategies to lower Lp(a) and mitigate residual cardiovascular risk.
• Targeting Lp(a) represents a key advancement in managing cardiovascular health.